Insider Purchases: Inside the Buy

Tag: SeanMcClain

Biotechnology laboratory where artificial intelligence designs therapeutic antibodies, featuring DNA helices, glowing neural-network interfaces, hair follicle imagery, and an upward stock chart symbolizing Absci's AI-powered drug discovery platform.

🧬 Absci (ABSI): A Director Bought After a 5× Rally. Here's Why the Story May Still Be in Its Early Innings.

When FUNanc1al first highlighted Absci around $4.18, the thesis centered on insider buying and an overlooked AI-biotech platform. Today the stock has nearly tripled, Eli Lilly has invested $100 million, institutions own over 80%, and another director is buying shares. Here's why the story may still be in its early innings.

Read entire article

Tags: ABS-201, ABS201, Absci, AbsciCorp, ABSI, antibody discovery, BiotechStocks, buy or sell ABSI, clinical-stage biotech, Eli Lilly, EliLilly, featured-insiders, FUNanc1al, FunStock, GenerativeAI, genomics, hair loss treatment, HairRegrowth, hub-insiders, insider buying, InsiderBuying, Mary Szela, MarySzela, NASDAQ, precision medicine, risks buying ABSI, SeanMcClain, ShortSqueeze, why buy ABSI